Referred to the House Committee on Energy and Commerce.
Reauthorizes and modifies the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through fiscal years 2026–2030. The bill updates program purposes to emphasize evidence-based screening, navigation and support services, and reducing disparities, and authorizes $235,000,000 for FY2026–2030.
Left praises disparity focus and navigation; right fears federal overreach and cost
Relative to its intended legislative type, this bill functions primarily as a substantive reauthorization and amendment of an existing federal public health program (NBCCEDP), with secondary administrative adjustments and a mandated GAO study.
Reauthorizes and modifies the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through fiscal years 2026–2030.
The bill updates program purposes to emphasize evidence-based screening, navigation and support services, and reducing disparities, and authorizes $235,000,000 for FY2026–2030.
It changes reporting timing and requirements and directs the GAO to report by September 30, 2027, on eligibility, trends, and access barriers.
Content is bipartisan-leaning and narrow, improving chances; authorization still requires appropriations and both-chamber consent, creating uncertainty.
Relative to its intended legislative type, this bill functions primarily as a substantive reauthorization and amendment of an existing federal public health program (NBCCEDP), with secondary administrative adjustments and a mandated GAO study. It provides clear purpose language, targeted statutory amendments, and specified oversight, but leaves several operational and fiscal details to implementing agencies or subsequent actions.
Left praises disparity focus and navigation; right fears federal overreach and cost
These are examples from the analysis, not a ranked list of the most-affected groups.
Left praises disparity focus and navigation; right fears federal overreach and cost
Likely broadly supportive because the bill reauthorizes a program serving low-income, uninsured women and explicitly targets disparities and navigation barriers.
The added emphasis on evidence-based strategies and a multiyear funding authorization are viewed positively.
Some impacts on how much funding reaches the most marginalized could be uncertain.
Generally supportive of reauthorizing a proven public-health screening program while stressing fiscal and implementation clarity.
Welcomes evidence-based language and GAO oversight but wants clearer cost estimates and measurable performance metrics.
Support is conditional on efficient use of funds and limited reporting burdens.
Mixed to somewhat opposed: supports cancer screening in principle but is concerned about expanded federal spending and program scope.
Skeptical of increased federal roles versus state-led or private solutions, and wary of new recurring authorizations without clear offsets.
GAO study may be acceptable as accountability, but overall federal expansion is concerning.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is bipartisan-leaning and narrow, improving chances; authorization still requires appropriations and both-chamber consent, creating uncertainty.
The bill has not accumulated any surfaced votes yet.
Left praises disparity focus and navigation; right fears federal overreach and cost
Content is bipartisan-leaning and narrow, improving chances; authorization still requires appropriations and both-chamber consent, creating…
Relative to its intended legislative type, this bill functions primarily as a substantive reauthorization and amendment of an existing federal public health program (NBCCEDP), with secondary administrative adjustments a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.